SCHEMBL6380412

SCHEMBL6380412

Nc1ccc(O)c(C=O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 12/20 0.57
CDK1 P06493 1/20 0.50
TRIM24 O15164 1/20 0.48
TRIM33 Q9UPN9 1/20 0.48
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
TNF P01375 1/20 0.47
CYP3A4 P08684 1/20 0.47
HSPD1 P10809 1/20 0.47
THRB P10828 1/20 0.47
CYP2C9 P11712 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
CASP1 P29466 1/20 0.47
CYP2C19 P33261 1/20 0.47
PTGS2 P35354 1/20 0.47
KDR P35968 1/20 0.47
BRCA1 P38398 1/20 0.47
RECQL P46063 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954779 1.00 ERN1 (0.57) ERN1CDK1TRIM24TRIM33KDM4E
Hydrochloric Acid SCHEMBL31191963 0.98 ERN1 (0.55) ERN1CDK1TRIM24TRIM33KDM4E
SCHEMBL29955412 0.84 ERN1 (0.67) ERN1
SCHEMBL2558331 0.84 ERN1 (0.67) ERN1
5-Bromosalicylaldehyde SCHEMBL28103357 0.82 ERN1 (0.81) ERN1CDK1KDM4EALDH1A1ALOX15
SCHEMBL6029813 0.82 TYR (0.52) ERN1TRIM24TRIM33KDM4EMEN1
SCHEMBL2554069 0.79 ERN1 (0.65) ERN1
SCHEMBL11664879 0.78 LMNA (0.46) KDM4EMEN1ALDH1A1CYP3A4THRB
SCHEMBL22630789 0.77 CA1 (0.46) KDM4EMEN1ALDH1A1TNFCYP3A4
SCHEMBL3679569 0.77 CA1 (0.46) KDM4EMEN1ALDH1A1TNFCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118652281-A Salamo-containing tetravalent platinum complex and preparation method and application thereof 巴音郭楞蒙古自治州人民医院 2024-09-17 CN claimed
US-9334176-B1 Method for removing organic dye from wastewater KING SAUD UNIVERSITY (SA) 2016-05-10 US claimed
US-5199954-A Comprising methylcellulose, sorbitol, inorganic metal salt, citric acid, panthenol and water; stability, discoloration inhibition SHISEIDO CO., LTD. (JP) 1993-04-06 US claimed
CN-122080106-A Oleanolic acid acylhydrazone derivative and preparation method and application thereof 2026-05-26 CN disclosed
CN-118652281-A Salamo-containing tetravalent platinum complex and preparation method and application thereof 巴音郭楞蒙古自治州人民医院 2024-09-17 CN disclosed
WO-2024178390-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2024-08-29 WO disclosed
US-20230349933-A1 METABOLIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) 2023-11-02 US disclosed
WO-2023094734-A1 LIGANDS SPECIFICALLY TARGETING VESICULAR GLUTAMATE TRANSPORTERS FOR SUPER-RESOLUTION IMAGING Sorbonne Université (FR) 2023-06-01 WO disclosed
US-20230123911-A1 MODULATION OF IMMUNE CELLS OCTAGON THERAPEUTICS, INC. 2023-04-20 US disclosed
CN-109152772-B Oral pharmaceutical composition of nicotinamide 康纳里斯研究院股份公司 2021-09-28 CN disclosed
US-9603940-B2 Metal salen complex derivative and process for production thereof IHI CORPORATION (JP) 2017-03-28 US disclosed
US-20020049154-A1 Bioconjugates and delivery of bioactive agents UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2002-04-25 US disclosed
EP-1172106-A2 Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists Pfizer Products Inc. (US) 2002-01-16 EP disclosed
US-6315978-B1 FOR SITE SPECIFIC RELEASE IN CELLS, TISSUES OR ORGANS UNIVERSITY OF UTAH, RESEARCH FOUNDATION 2001-11-13 US disclosed
CN-1056373-C Process for preparing fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles PFIZER (US) 2000-09-13 CN disclosed
EP-1007533-A1 BIOCONJUGATES AND DELIVERY OF BIOACTIVE AGENTS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2000-06-14 EP disclosed
WO-1998008859-A1 BIOCONJUGATES AND DELIVERY OF BIOACTIVE AGENTS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 1998-03-05 WO disclosed
US-5199954-A Comprising methylcellulose, sorbitol, inorganic metal salt, citric acid, panthenol and water; stability, discoloration inhibition SHISEIDO CO., LTD. (JP) 1993-04-06 US disclosed
US-4678851-A FIBER-RACTIVE CIBA-GEIGY CORPORATION (US) 1987-07-07 US disclosed
EP-0159962-A2 Fibre-reactive chromium or cobalt complexes, their preparation and their use CIBA-GEIGY AG (CH) 1985-10-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230123911-A1 MODULATION OF IMMUNE CELLS IMPDH2, IMPDH1, CD74 ERN1 1686/4885CDK1 3159/4885TRIM24 2208/4885
US-20020049154-A1 Bioconjugates and delivery of bioactive agents CASP3, CASP6, RNPEP ERN1 3016/4885CDK1 644/4885TRIM24 2885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.